|
1
|
Geiss-Friedlander R and Melchior F:
Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol.
8:947–956. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meluh PB and Koshland D: Evidence that the
MIF2 gene of Saccharomyces cerevisiae encodes a centromere
protein with homology to the mammalian centromere protein CENP-C.
Mol Biol Cell. 6:793–807. 1995.PubMed/NCBI
|
|
3
|
Shen Z, Pardington-Purtymun PE, Comeaux
JC, Moyzis RK and Chen DJ: UBL1, a human ubiquitin-like protein
associating with human RAD51/RAD52 proteins. Genomics. 36:271–279.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okura T, Gong L, Kamitani T, Wada T, Okura
I, Wei CF, Chang HM and Yeh ET: Protection against Fas/APO-1- and
tumor necrosis factor-mediated cell death by a novel protein,
sentrin. J Immunol. 157:4277–4281. 1996.PubMed/NCBI
|
|
5
|
Seeler JS and Dejean A: Nuclear and
unclear functions of SUMO. Nat Rev Mol Cell Biol. 4:690–699. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wadosky KM and Willis MS: The story so
far: post-translational regulation of peroxisome
proliferator-activated receptors by ubiquitination and SUMOylation.
Am J Physiol Heart Circ Physiol. 302:H515–H526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gong L, Li B, Millas S and Yeh ET:
Molecular cloning and characterization of human AOS1 and UBA2,
components of the sentrin-activating enzyme complex. FEBS Lett.
448:185–189. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muller S, Berger M, Lehembre F, Seeler JS,
Haupt Y and Dejean A: c-Jun and p53 activity is modulated by SUMO-1
modification. J Biol Chem. 275:13321–13329. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu G and Warbrick E: The p66 and p12
subunits of DNA polymerase delta are modified by ubiquitin and
ubiquitin-like proteins. Biochem Biophys Res Commun. 349:360–366.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanaka K, Nishide J, Okazaki K, Kato H,
Niwa O, Nakagawa T, Matsuda H, Kawamukai M and Murakami Y:
Characterization of a fission yeast SUMO-1 homologue, pmt3p,
required for multiple nuclear events, including the control of
telomere length and chromosome segregation. Mol Cell Biol.
19:8660–8672. 1999.PubMed/NCBI
|
|
11
|
Bachant J, Alcasabas A, Blat Y, Kleckner N
and Elledge SJ: The SUMO-1 isopeptidase Smt4 is linked to
centromeric cohesion through SUMO-1 modification of DNA
topoisomerase II. Mol Cell. 9:1169–1182. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Azuma Y, Arnaoutov A and Dasso M: SUMO-2/3
regulates topoisomerase II in mitosis. J Cell Biol. 163:477–487.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu N, Kong X, Ji Z, Zeng W, Potts PR,
Yokomori K and Yu H: Scc1 sumoylation by Mms21 promotes sister
chromatid recombination through counteracting Wapl. Genes Dev.
26:1473–1485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McAleenan A, Cordon-Preciado V,
Clemente-Blanco A, Liu IC, Sen N, Leonard J, Jarmuz A and Aragón L:
SUMOylation of the α-kleisin subunit of cohesin is required for DNA
damage-induced cohesion. Curr Biol. 22:1564–1575. 2012.
|
|
15
|
Luo K, Zhang H, Wang L, Yuan J and Lou Z:
Sumoylation of MDC1 is important for proper DNA damage response.
EMBO J. 31:3008–3019. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ferenci P, Fried M, Labrecque D, Bruix J,
Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA,
et al: Hepatocellular carcinoma (HCC): a global perspective. J Clin
Gastroenterol. 44:239–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Correia AL and Bissell MJ: The tumor
microenvironment is a dominant force in multidrug resistance. Drug
Resist Updat. 15:39–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Doublier S, Belisario DC, Polimeni M,
Annaratone L, Riganti C, Allia E, Ghigo D, Bosia A and Sapino A:
HIF-1 activation induces doxorubicin resistance in MCF7 3-D
spheroids via P-glycoprotein expression: a potential model of the
chemo-resistance of invasive micropapillary carcinoma of the
breast. BMC Cancer. 12:42012. View Article : Google Scholar
|
|
19
|
Brökers N, Le-Huu S, Vogel S, Hagos Y,
Katschinski DM and Kleinschmidt M: Increased chemoresistance
induced by inhibition of HIF-prolyl-hydroxylase domain enzymes.
Cancer Sci. 101:129–136. 2010.PubMed/NCBI
|
|
20
|
Fabregat I, Roncero C and Fernández M:
Survival and apoptosis: a dysregulated balance in liver cancer.
Liver Int. 27:155–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Homann N, Pauligk C, Luley K, et al:
Pathological complete remission in patients with oesophagogastric
cancer receiving preoperative 5-fluorouracil, oxaliplatin and
docetaxel. Int J Cancer. 130:1706–1713. 2012. View Article : Google Scholar
|
|
22
|
Kitagawa K, Kawada K, Morita S, et al:
Prospective evaluation of corrected QT intervals and arrhythmias
after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil
in women with breast cancer. Ann Oncol. 23:743–747. 2012.
View Article : Google Scholar
|
|
23
|
Nagai S, Davoodi N and Gasser SM: Nuclear
organization in genome stability: SUMO connections. Cell Res.
21:474–485. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cai Q and Robertson ES: Ubiquitin/SUMO
modification regulates VHL protein stability and nucleocytoplasmic
localization. PLoS One. 5:e126362010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ding B, Sun Y and Huang J: Overexpression
of SKI oncoprotein leads to p53 degradation through regulation of
MDM2 protein sumoylation. J Biol Chem. 287:14621–14630. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bettermann K, Benesch M, Weis S and
Haybaeck J: SUMOylation in carcinogenesis. Cancer Lett.
316:113–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo WH, Yuan LH, Xiao ZH, Liu D and Zhang
JX: Overexpression of SUMO-1 in hepatocellular carcinoma: a latent
target for diagnosis and therapy of hepatoma. J Cancer Res Clin
Oncol. 137:533–541. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kessler JD, Kahle KT, Sun T, et al: A
SUMOylation-dependent transcriptional subprogram is required for
Myc-driven tumorigenesis. Science. 335:348–353. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Q, Xia N, Li T, et al: SUMO-specific
protease 1 promotes prostate cancer progression and metastasis.
Oncogene. 32:2493–2498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wartenberg M, Ling FC, Muschen M, et al:
Regulation of the multidrug resistance transporter P-glycoprotein
in multicellular tumor spheroids by hypoxia-inducible factor
(HIF-1) and reactive oxygen species. FASEB J. 17:503–505. 2003.
|
